Jamme et al. reported advanced-stage NSCLC patients with METΔex14 carrying alterations in the PI3K pathway, including PTEN loss and PIK3CA mutations, which can be associated with resistance to MET-TKI [75]. The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.